HFrEF pharmacological treatment: beta blockers

Beggs, S. A. S. and Gardner, R. S. (2018) HFrEF pharmacological treatment: beta blockers. In: Camm, A. J., Lüscher, T. F., Maurer, G. and Serruys, P. W. (eds.) ESC Textbook of Cardiovascular Medicine. Oxford University Press: Oxford, UK, pp. 1851-1862. ISBN 9780198784906 (doi: 10.1093/med/9780198784906.003.0426)

Full text not currently available from Enlighten.


By incremental steps over several decades of research, beta blockers have evolved ‘from bench to bedside’, emerging as a keystone of modern optimal pharmacotherapy for heart failure. This chapter starts by detailing the story of their development, focusing on the randomized trials that established their clinical efficacy in reducing hospitalization and death. Subsequently, issues such as the potential heterogeneity among different beta-blocker agents and the appropriate dose targets in heart failure are discussed. Advice regarding the initiation, titration, and discontinuation of beta blockers is presented, providing practical guidance for healthcare professionals who manage patients with heart failure. Finally, the chapter explores the evidence underlying the use of beta blockers in specific populations, such as elderly patients, black patients, and those with atrial fibrillation, obstructive airways disease, or asymptomatic left ventricular systolic dysfunction.

Item Type:Book Sections
Additional Information:3rd edition
Glasgow Author(s) Enlighten ID:Gardner, Professor Roy and Beggs, Dr Simon
Authors: Beggs, S. A. S., and Gardner, R. S.
College/School:College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health
Publisher:Oxford University Press

University Staff: Request a correction | Enlighten Editors: Update this record